Relay Therapeutics CEO Patel sells $219k in shares

Published 10/07/2025, 22:00
Relay Therapeutics CEO Patel sells $219k in shares

Relay Therapeutics (NASDAQ:RLAY) President and CEO Sanjiv Patel sold a total of 61,379 shares of common stock on July 9, 2025, for approximately $219,123. The sales were executed at a price of $3.57 per share, with the stock currently trading at $3.73, near its 52-week low of $1.77. According to InvestingPro data, analysts maintain a bullish stance on the company with a consensus "Buy" rating.

The sales were to cover income tax withholding obligations upon the vesting of restricted stock units. Following the transactions, Patel directly owns 765,288 shares of Relay Therapeutics.

Patel also indirectly owns 199,548 shares through The Patel Family Irrevocable Trust of 2019 and 687,355 shares through The SSP Irrevocable Trust of 2020.

In other recent news, Relay Therapeutics has announced promising clinical data for its investigational drug RLY-2608, aimed at treating advanced breast cancer with a specific mutation. The updated results, presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, showed a median progression-free survival of 10.3 months overall and 11.0 months in second-line patients. The ReDiscover study, which is evaluating RLY-2608’s safety and efficacy, reported a clinical benefit rate of 67%, with 81% of patients experiencing tumor reductions. Relay Therapeutics plans to initiate a Phase 3 study, ReDiscover-2, in mid-2025 to further investigate the drug’s potential.

Additionally, the company’s stock rating was reaffirmed as Market Outperform by Citizens JMP, with a price target of $12.00, following the presentation of the trial data. The company continues to lead in the PI3K inhibitor space, with no unexpected developments from competitors at the ASCO conference. Relay Therapeutics is also exploring combination treatments, including partnerships with Pfizer (NYSE:PFE) and others, to enhance the efficacy of RLY-2608. Management emphasized the importance of interactions at ASCO to facilitate the upcoming Phase 3 trial.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.